Extracellular Vesicle-Based Targeting of CD33-Mediated Pathology for Alzheimer’s Disease Therapy

2015 to 2016

Alzheimer’s disease (AD) is a devastating disease for patient and family alike. Unfortunately, there is no effective treatment and conventional, drug based therapies have failed. Our lab has developed a therapeutic virus vector that the body’s immune defenses will tolerate and that efficiently delivers nucleic acid-based material into cells. In this case, the material is a gene therapy specifically tailored to manipulate the expression of CD33, a gene seen in mouse models to slow beta amyloid clearance and thus contribute to Alzheimer’s disease pathology.


Funding to Date

$300,000

Focus

Genes to Therapies™ / Drug Screening, Translational Research

Researchers

Casey A. Maguire, Ph.D.